摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3-((1R,3R)-6-fluoro-1-(6-fluoro-3-(2-((3-fluoropropyl)amino)ethoxy)-2-methylphenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropanoic acid

中文名称
——
中文别名
——
英文名称
(S)-3-((1R,3R)-6-fluoro-1-(6-fluoro-3-(2-((3-fluoropropyl)amino)ethoxy)-2-methylphenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropanoic acid
英文别名
US10221173, Example 57;(2S)-3-[(1R,3R)-6-fluoro-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid
(S)-3-((1R,3R)-6-fluoro-1-(6-fluoro-3-(2-((3-fluoropropyl)amino)ethoxy)-2-methylphenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropanoic acid化学式
CAS
——
化学式
C28H34F3N3O3
mdl
——
分子量
517.591
InChiKey
JOFYCYZGTXIWEJ-ANAQZDLVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    37
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    77.6
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Chemical compounds
    申请人:AstraZeneca AB
    公开号:US10221173B2
    公开(公告)日:2019-03-05
    The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    本说明书涉及式 (I) 化合物: 及其药学上可接受的盐、用于制备它们的工艺和中间体、含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
  • Selective estrogen receptor down-regulators
    申请人:AstraZeneca AB
    公开号:US10590132B2
    公开(公告)日:2020-03-17
    The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    本说明书涉及式 (I) 化合物: 及其药学上可接受的盐、用于制备它们的工艺和中间体、含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
  • ESTROGEN RECEPTOR MODULATORS
    申请人:Astrazeneca AB
    公开号:EP3494116B1
    公开(公告)日:2019-10-23
  • CHEMICAL COMPOUNDS
    申请人:AstraZeneca AB
    公开号:US20180282325A1
    公开(公告)日:2018-10-04
    The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
  • Selective Estrogen Receptor Down-Regulators
    申请人:AstraZeneca AB
    公开号:US20200239468A1
    公开(公告)日:2020-07-30
    The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
查看更多